NYSE$AMWL
American Well Corp · Q4 2024 earnings
Q4 2024 earnings · · After market close · Investor relations
Briefing
Amwell announced its financial results for the fourth quarter and full year ended December 31, 2024.
Amwell reported a total revenue of $71.0 million for Q4 2024, with a net loss of ($44.6) million. The company achieved a gross margin of 48% and an adjusted EBITDA of ($22.8) million, showing an improvement compared to the previous quarter.
- Total revenue for Q4 2024 was $71.0 million.
- Net loss for Q4 2024 was ($44.6) million, a slight increase from ($44.0) million in Q3 2024.
- Adjusted EBITDA for Q4 2024 was ($22.8) million, an improvement from ($31.0) million in Q3 2024.
- Gross margin for Q4 2024 was 48%.
Headline financials
Revenue & EPS history
American Well · Revenue · Quarterly
$71M
Revenue by segment
American Well · $28.4M total across 1 segment · Q3 2023
- Subscription Revenue$28.4M-11.0%100.0%
Forward guidance
Amwell provided financial guidance for 2025, expecting revenue between $250 million and $260 million, AMG visits between 1.3 million and 1.35 million, and adjusted EBITDA between ($55) million and ($45) million. The company also aims to achieve positive cash flow in 2026.
Tailwinds
- Projected revenue for 2025 is between $250 million and $260 million.
- Anticipated AMG visits for 2025 are between 1.3 million and 1.35 million.
- Adjusted EBITDA for 2025 is expected to be between ($55) million and ($45) million, indicating an improvement from 2024.
- Q1 2025 revenue is projected to be between $59 million and $61 million.
- The company's objective is to achieve positive cash flow in 2026.
Headwinds
- The 2025 revenue guidance reflects the divestiture of Amwell Psychiatric Care.
- Adjusted EBITDA for 2025 is still projected to be negative.
- Q1 2025 adjusted EBITDA is expected to be negative, between ($18) million and ($20) million.
- The company does not provide a GAAP reconciliation for forward-looking Adjusted EBITDA due to inherent difficulties in forecasting certain amounts.
- Future results may be materially less than projected Adjusted EBITDA due to various deductions not included in GAAP calculations.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2024
+1.4%
Avg return
Earnings day
+2.1%
Avg return
5 days after
-2.2%
Avg return
30 days after
41%
9 / 22 earnings
Positive
+33.8%
Q2 2024
Best reaction
-20.9%
Q1 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.0% | +27.2% | +34.0% | |
| Q4 2025 | +24.7% | +34.9% | +29.8% | |
| Q3 2025 | -9.5% | -20.0% | -20.6% | |
| Q1 2025 | +19.7% | +9.5% | +8.9% | |
| Q4 2024 | -5.0% | -3.6% | -35.5% | |
| Q3 2024 | -5.0% | -5.4% | -0.7% | |
| Q2 2024 | +33.8% | +13.9% | -1.1% | |
| Q1 2024 | +2.0% | +11.4% | -16.3% | |
| Q4 2023 | +23.6% | +20.8% | -16.0% | |
| Q3 2023 | +14.5% | +4.3% | +11.1% | |
| Q2 2023 | -8.3% | -13.9% | -35.2% | |
| Q1 2023 | -3.9% | -2.9% | +17.9% | |
| Q4 2022 | -13.1% | -19.2% | -37.3% | |
| Q3 2022 | -2.2% | +14.9% | -8.3% | |
| Q2 2022 | +9.2% | +6.8% | -4.8% | |
| Q1 2022 | -10.8% | +8.8% | +37.6% | |
| Q4 2021 | +7.2% | +1.0% | -8.0% | |
| Q3 2021 | -7.4% | -3.7% | -29.7% | |
| Q2 2021 | +0.7% | -1.7% | +0.8% | |
| Q1 2021 | -20.9% | -5.7% | +9.5% | |
| Q4 2020 | -4.1% | -10.8% | -1.5% | |
| Q3 2020 | -11.9% | -19.8% | +17.1% | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro